We’re improving your experience!
Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CD19 t-haNK cells |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
CD19 t-haNK cells are activated natural killer (NK) cells engineered to express a high affinity Fc receptor and a chimeric antigen receptor (CAR) targeting CD19, which potentially induce tumor cell killing (PMID: 35400595). |
| DrugClasses | CD19 Immune Cell Therapy 65 |
| CAS Registry Number | NA |
| NCIT ID | NA |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| CD19 t-haNK cells | CD19 t-haNK cells | 0 | 0 |
| CD19 t-haNK cells + Nogapendekin alfa inbakicept + Rituximab | CD19 t-haNK cells Nogapendekin alfa inbakicept Rituximab | 0 | 1 |
| CD19 t-haNK cells + Rituximab | CD19 t-haNK cells Rituximab | 0 | 1 |
CKB BOOST